Literature DB >> 27662623

Role and therapeutic potential of CDK12 in human cancers.

Rosaria Chilà1, Federica Guffanti1, Giovanna Damia2.   

Abstract

Phosphorylation of the RNA polymerase II C-terminal domain by cyclin-dependent kinases (CDKs) is important for productive transcription. Deregulated transcription-CDKs have been reported in different human cancers. Until recently CDK9 was the only transcription-CDK with a causative role in cancer, but evidence is cumulating of the importance of CDK12. This review summarizes the role of CDK12 in transcription and RNA processing, in maintaining genomic stability/integrity and in tumorigenesis. CDK12 mutations have been reported in many cancers and have been suggested as a cause of defective DNA repair in ovarian carcinoma. CDK12 may have a role as a new therapeutic target in oncology.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CDK12; DNA repair; Ovarian cancer; Transcription

Mesh:

Substances:

Year:  2016        PMID: 27662623     DOI: 10.1016/j.ctrv.2016.09.003

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  18 in total

1.  Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

Authors:  Melissa A Reimers; Steven M Yip; Li Zhang; Marcin Cieslik; Mallika Dhawan; Bruce Montgomery; Alexander W Wyatt; Kim N Chi; Eric J Small; Arul M Chinnaiyan; Ajjai S Alva; Felix Y Feng; Jonathan Chou
Journal:  Eur Urol       Date:  2019-10-20       Impact factor: 20.096

Review 2.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

3.  The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.

Authors:  F Guffanti; R Fruscio; E Rulli; G Damia
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

4.  Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Authors:  Federica Guffanti; Maddalena Fratelli; Monica Ganzinelli; Marco Bolis; Francesca Ricci; Francesca Bizzaro; Rosaria Chilà; Federica Paola Sina; Robert Fruscio; Michela Lupia; Ugo Cavallaro; Maria Rosa Cappelletti; Daniele Generali; Raffaella Giavazzi; Giovanna Damia
Journal:  Oncotarget       Date:  2018-05-15

Review 5.  The emerging roles of CDK12 in tumorigenesis.

Authors:  Hana Paculová; Jiří Kohoutek
Journal:  Cell Div       Date:  2017-10-27       Impact factor: 5.130

Review 6.  CDK12: A Potent Target and Biomarker for Human Cancer Therapy.

Authors:  Shujing Liang; Lifang Hu; Zixiang Wu; Zhihao Chen; Shuyu Liu; Xia Xu; Airong Qian
Journal:  Cells       Date:  2020-06-18       Impact factor: 6.600

Review 7.  Therapeutic targeting of transcriptional cyclin-dependent kinases.

Authors:  Matthew D Galbraith; Heather Bender; Joaquín M Espinosa
Journal:  Transcription       Date:  2018-11-09

Review 8.  Exploiting Replication Stress as a Novel Therapeutic Intervention.

Authors:  Jeffrey C Martin; Tamara J Hoegel; Miranda L Lynch; Anna Woloszynska; Thomas Melendy; Joyce E Ohm
Journal:  Mol Cancer Res       Date:  2020-10-05       Impact factor: 6.333

9.  Characterizing CDK12-Mutated Prostate Cancers.

Authors:  Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 13.801

10.  The Ethnic-Specific Spectrum of Germline Nucleotide Variants in DNA Damage Response and Repair Genes in Hereditary Breast and Ovarian Cancer Patients of Tatar Descent.

Authors:  Olga I Brovkina; Leila Shigapova; Daria A Chudakova; Marat G Gordiev; Rafael F Enikeev; Maxim O Druzhkov; Dmitriy S Khodyrev; Elena I Shagimardanova; Alexey G Nikitin; Oleg A Gusev
Journal:  Front Oncol       Date:  2018-10-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.